Last updated on October 2018

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

Brief description of study

To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression

Clinical Study Identifier: NCT03118947

Contact Investigators or Research Sites near you

Start Over

Michigan Neurology Associates
Clinton Township, MI United States